Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Krenetics Pharmaceutical School's second quarter 2025 financial results conference call. At this time, all participants are on listen-only mode. Following the management's prepared remarks, we will hold a question and answer session. In order to raise a question, please signal by pressing star followed by one on your telephone keypad. To remove yourself from the line of questioning, it will be star followed by two. And I would like to turn the call over to Gayathri De Walker, Head of Investor Relations. Please go ahead. Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss the second quarter 2025 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer, Dr. Dana Pizzuti, Chief Medical and Development Officer, Isabel Calazono, Chief Commercial Officer, and Toby Schoke, Chief Financial Officer. In addition, Dr. Steve Betts, Founder and Chief Scientific Officer, and Dr. Alan Krasner, Chief Endocrinologist, will also be joining for the Q&A portion. Please note there's a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Kinetics website. In addition, a press release was issued earlier today and is also available on the corporate website. Slide two. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. In particular, today we will be reviewing our commercial...